Panel discussion: The benefits of AI within drug discovery

Panel discussion: The benefits of AI within drug discovery

Wednesday, October 9, 2024 10:00 AM to 10:40 AM · 40 min. (Europe/Brussels)
Plenary
Keynote
Keynote Theatre

Information

Have we extracted all the value we can from public data?

Hype vs hope: where are we in terms of expectations from AI and practical reality? Does this vary depending on which use case we are considering?

Is more data, or the latest algorithmic approach always better?

How best to measure impact and ROI from the application of AI?

BenevolentAIBooth 1116At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Registered attendees

Aaron Mitchell
Aaron Mitchell
PrincipalZS Associates
abiramy sinnadurai
abiramy sinnadurai
MarketingWhiteLab Genomics
Adrian Jonas
Adrian Jonas
Chief Analyst for the North West RegionNHS England

Log in